BCAL Diagnostics (ASX:BDX) Long-Term Debt: A$2.98 Mil (As of Dec. 2025)


What is BCAL Diagnostics Long-Term Debt?

BCAL Diagnostics ASX:BDX +1.39% Long-Term Debt is A$2.98 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

BCAL Diagnostics's Long-Term Debt for the quarter that ended in Dec. 2025 was A$2.98 Mil.

BCAL Diagnostics's quarterly Long-Term Debt declined from Dec. 2024 (A$0.84 Mil) to Jun. 2025 (A$0.12 Mil) but then increased from Jun. 2025 (A$0.12 Mil) to Dec. 2025 (A$2.98 Mil).

BCAL Diagnostics's annual Long-Term Debt increased from Jun. 2023 (A$0.00 Mil) to Jun. 2024 (A$0.40 Mil) but then declined from Jun. 2024 (A$0.40 Mil) to Jun. 2025 (A$0.12 Mil).

BCAL Diagnostics  (ASX:BDX) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

BCAL Diagnostics Long-Term Debt Related Terms

BCAL Diagnostics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for BCAL Diagnostics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BCAL Diagnostics Long-Term Debt Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Long-Term Debt
0.00 0.00 0.40 0.12

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.14 0.40 0.84 0.12 2.98
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of A$2.98 Mil mean?
BCAL Diagnostics (ASX:BDX) has a Long-Term Debt of A$2.98 Mil as of Dec. 2025.
Is BCAL Diagnostics' Long-Term Debt too high?
BCAL Diagnostics' current Long-Term Debt is A$2.98 Mil.
How does BCAL Diagnostics' Long-Term Debt compare to TMO and DHR?
BCAL Diagnostics' Long-Term Debt of A$2.98 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Diagnostics & Research company?
A good Long-Term Debt depends on the Medical Diagnostics & Research industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. BCAL Diagnostics's current Long-Term Debt is A$2.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current Long-Term Debt of A$2.98 Mil. The current Long-Term Debt is A$2.98 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current Long-Term Debt is A$2.98 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BCAL Diagnostics Business Description

Address 50 Clarence Street, Suite 506, Level 5, Sydney, NSW, AUS, 2000
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.